• Grant
  • International
Log in

Login to your account

Username *
Password *
Remember Me

International Grant


International grants in 2014
 
NO NAME TYPE TITLE SPONSOR
1
Dr. Imran Ahmad, Perubatan Keluarga
Geran Luar
A Comparative Study Of Drug Addiction Rehabilitation Between Japan and Malaysia: Feasibility Of Setting Up Similar Centers in Malaysia
The Sumitomo Foundation
 

International grants in 2013
 
NO NAME TYPE TITLE SPONSOR
1
PM Dr. Rohana Abdul Jalil, Perubatan Masyarakat
Geran Luar
School Lunch Program 'Kyushoku' : What Malaysian Can Learn From Japan
Sumitomo Foundation, Japan
 

International grants in 2012
 
NO NAME TYPE TITLE SPONSOR
1
Dr. Wan Mohd Izani Wan Mohamad, Perubatan
Kajian Klinikal
A Phase 3, Ranomized, Double-Blind, Placebo-Controlled, Parellel Group Study To Evaluate The Efficacy and Safety of Ranolazine When Added To Glimepiride in Subjects With Type 2 Diabetes Mellitus
Gilead Sciences, Inc
2
Dr. V. M. K Bhavaraju, Perubatan Nuklear
Kajian Klinikal
Study Of A Randomized Double-Blind, Placebo-Controlled Study To Evaluate The Long Term Safety And Efficacy of Darbepoetin Alfa Administered at 500mg Once-Every-3 Weeks in The Anemic Subjects With Advanced Stage Non-Small Cell lung Cancer Receiving multi-Cycle Chemotherapy
International (Hong Kong)
3
PM Dr Biswa Mohan Biswal, Perubatan Nuklear
Kajian Klinikal
Pivotal Study In Breast Cancer Patients Investigatoring Efficacy and Safety of LA-EP2006 and Neulasta R
International (UK)
4
Dr. Nor Aizal Che Hamzah, Perubatan
Kajian Klinikal
A Phase III, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ Ribavirin In Chronic HCV Genotype Iil28b cc Subjects (protocol No:P07755) (Also Known MK3034-040-01) MK3034-040 Site No.344 (the Protocol)
MERCK SHARP & DOHME (I.A) CORP
5
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
Study The Safety And/Or Efficacy of MK0431 Sitagliptin (The Study Drug) / Study of MK0431 in Pediatrik Patients With Tyoe 2 Diabetes
MERCK SHARP & DOHME (I.A) CORP
6
PM Dr. Kamarul Aryffin Baharuddin, Perubatan Kecemasan
Geran Luar
A Comprehensive Study on Home Care Nursing Between Japan and Malaysia
SUMITOMO FOUNDATION
 

International grants in 2011
 
NO NAME TYPE TITLE SPONSOR
1
PM Dr Biswa Mohan Biswal, Perubatan Nuklear
Kajian Klinikal
A Phase 3, randomized, double-Blinded Study of IMC-1121B and besr Supportive cars (BSC) versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum-or Fluoropyrimidine-Containing Combination Therapy
Quintiles
2
PM Dr. Muzaimi Mustapha, Neurosains
Geran Luar
CB1 Cannabinoid Receptor As Cerebellar Molecular Targets Of Mitragyna Speciosa (Ketum) Addiction In The Brain Of Mitragynine-Sensitised Albino Wistar Rats
COMSTECH-TWAS
3
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
A 24 Week, Randomized, Double-Blind, Active-Controlled, Parallel Group Trial To Assess the Superiority of Oral Linagliptin and Metformin Compared to Linagliptin Monotheraphy in Newly Diagnosed, Treatmentnaive, Uncontrolled Type 2 Diabetes Mellitus Patients
ICON Clinical Research limited (Ireland)
4
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel Group, 18-Week Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin Compare With Placebo Alone or in Combination With a Sulphonylurea
Johnson & Johnson Sdn Bhd
5
PM Dr. Rahimah Zakaria, Fisiologi
Geran Luar
The Combined Effects of Ovariectomy and Chronic Social Instability Stress on Cognitive Functions, Depressive Behaviour and Biochemical Changes in female Rates Treated with Tualang Honey
Ministry Health of Oman
6
Prof Dr Van Rostenberghe Hans Luc Aster, Pediatrik
Geran Luar
SEA-URCHIN: South East Asia - Using Research For Change In Hospital - Acquire Infection in Neonates
Monash University, Victoria
7
Dr. Azlan Husin, Perubatan
Kajian Klinikal
A Randomized, Controlled, Double- Blind Phase III Trial To Compare The Efficacy, Safety and Pharmacokinetics of GP2013 Plus CVP vs. MabThera(R) Maintenance Therapy in Patients With Previously Untreated,Advanced Stage Follicular Lymphoma
PPD Development (S) Pte Ltd
 

International grants in 2010
 
NO NAME TYPE TITLE SPONSOR
1
Dr. V. M. K Bhavaraju, Perubatan Nuklear
Kajian Klinikal
A Randomized, double Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)
Amgen (Asia) Limited
2
Prof Dr Nik Mohamed Zaki Nik Mahmood, O&G
Kajian Klinikal
A Phase 3, Randomized, Double-Blind Trial Of Weekly Paclitaxel Plus AMG 386 or Placebo In Women With recurrent Partially Platinum Sensitive Or resistant Epithelial Ovarian, Primary Peritoneal Or Fallopian Tube Cancers
AMGEN Inc.
3
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
1218.66: A Randomized, Double Blind, Placebo-Blind, Placebo-Controlled parallel group Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug Naive or previously Treated (6 Weeks Washout) Type 2 Diabetic Patients With Insufficient Glycaemic Control
Boehringer Ingelheim
4
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
1218.65: A Randomised, Double-Blind, Placebo-Controlled Parallel Group efficacy and Safety Study of Linagliptin (5 mg Administered orally once daily) Over 24 Weeks in type 2 Diabetic Patients with Insufficient Glycaemic Control Despite Metformin Therapy
Boehringer Ingelheim
5
Prof Dr. Suzina Sh. Ab. Hamid, Unit Bank Tisu
Geran Luar
Studies On Functional Properties Of Processed and Irradiated Human Amniotic Membranes
IAEA
6
PM Dr Biswa Mohan Biswal, Perubatan Nuklear
Kajian Klinikal
A Phase 3, Randomized, Double Blind Study Of IMC-1121B And Best Supportive Care (BSC) Versus Placebo And BSC In The Treatment Of Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma Following Disease Progression On First-Line Platinum- Or Fluoropyrimidine- Containing Combination Therapy
ImClone LLC
7
Dr. Mohd Azhar Mohd Yasin, Psikiatri
Kajian Klinikal
Safety, Tolerability and Treatment Response Of Paliperidone Palmitate In Subjects With Schizophrenia When Switching From Oral Antipsychotics
Jenssen-Cilag (Johnson & Johnson Sdn Bhd)
8
Prof Dr Jafri Malin Abdullah, Neurosains
Geran Luar
Surgical Trial In Lobar Intracranial Haemorrhage, STICH II
NEWCASTLE UPON TYNE HOSPITALS NHS TRUST
9
Prof Dr Wan Mohamad Wan Bebakar, Perubatan
Kajian Klinikal
NN1250-3586
BEGINTM: Once Asia A PAn Asian Trial Comparing Efficacy And Safety Of Insulin NN1250 And Insulin Glargine As Add-On To OAD(s) In Subjects With Type 2 Diabetes, A 26-Week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-To-Target Trial Comparing The Efficacy and Safety SIBAAnd Insulin Glargine, Both Injected Once Daily As Add On To Current OAD Treatment In Insulin Naive Subjects With Type 2 Diabetes mellitus Qualifying For More Intensified Treatment, Trial Phase: 3a
Novo Nordisk
10
Prof Dr Wan Mohamad Wan Bebakar, Perubatan
Kajian Klinikal
NN5401-3597
BOOSTTM: Intensify All, A Pan Asian Trial ComparingEfficacy And Safety Of NN5401 And Biphasic Aspart 30 in Type 2 Diabetes, A 26-Week Trial, Randomised, Open-Label, Two-Arm, Parallel Group, Treat-To-Target Study Comparing Efficacy and Safety Of The Soluble Insulin Analogue Combination (SIAC) Twice Daily With Biphasic Insulin Aspart 30 Twice Daily, With Or Without Metformin In Subjects With Type 2 Diabetes In Inadequate Glycemic Control On Once Or Twice Daily Insulin Regimen With Or Without Metformin, Trial Phase 3a
Novo Nordisk
11
Dr. Zarina Zainan Abidin, Psikiatri
Kajian Klinikal
A Randomized, double-Blind, Placebo-Controlled, Parallel-Group Study Of Paliperidone Palmitate Evaluating Time To Relapse in Subjects with Schizoaffective Disorder
Ortho-McNeil Janssen Scientific Affairs
12
PM Dr. Kirnpal Kaur Banga Singh, Mikrobiologi
Geran Luar
To Provide Malaysia Bacterial Isolates For The Sentry Antimicrobial Surveillance Program in 2010
Sentry Antimicrobial Surveillance
 

International grants in 2009
 
NO NAME TYPE TITLE SPONSOR
1
Prof Dr Abdul Aziz Baba, Perubatan
Kajian Klinikal
FORTIS-M: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients with Non-Small Lung Cancer Who Have Failed Two or More Treatment Regimens.
Agennix Incorporated
2
Dr. V. M. K Bhavaraju, Perubatan Nuklear
Kajian Klinikal
A Randomized, Multicenter, Open-Label, Phase 3. Study To Compare The Efficacy and safety Of Panitumumab And Cetuximab In Subjects With Previously Treated, Wild-Type KRAS, Metastatic Colorectal Cancer
Amgen (Asia) Ltd
3
Prof Dr. Baharudin Abdullah, ORL
Kajian Klinikal
A Phase II, Randomized Controlled Trial of Foscan¨ - Mediated Photodynamic Therapy Versus Brachytherapy in Patients with Recurrent or Persistent Nasopharngeal Carcinoma
Clinical Research Centre
4
Prof Dr Wan Mohamad Wan Bebakar, Perubatan
Kajian Klinikal
A Randomised, Double Blind, Placebo-Controlled, 3 Parallel Group Efficacy And safety Study Of Linagliptin 2.5 mg Twice Daily Versus 5mg Once Daily Over 12 Weeks As Add-On Therapy To A Twice Daily Dosing Regimen Of Metformin In Patients With Type 2 Diabetes Mellitus And Insufficient Glycaemic Control
Boehringer Ingelheim
5
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide when Used in Combination with Metformin in Subjects with Type 2 Diabetes.
Brit Insurance Limited
6
PM Dr Zurkurnai Yusof, Perubatan
Kajian Klinikal
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group,  Multicenter, Multi-National Study For Evaluation of Efficacy and Safety of DU-176B versus warfarin in subjetcs with atrial fibrillation Ð Effective aNticoaGulation with Factor xA next Generation in Atrial Fibrillation (ENGAGE AF Ð TIMI 48).
Daiichi Sankyo Pharma Development
7
PM Dr Zurkurnai Yusof, Perubatan
Kajian Klinikal
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Who are Medically Managed Ð The TRILOGY ACS Study.
Eli Lilly & Co
8
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
A Multicenter, Randomized,Open Label, Active Controlled Study To Compare The efficacy, safety And Tolerability Of Taspoglutide (RO5073031) Versus Insulin Glargine In Insulin-Naive Type 2 Dabetic patients Inadequately Controlled With Metformin and Sulfonylurea Combination Therapy
F. Hoffmann - La Roche AG
9
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Assess The Effects Of Taspoglutide (RO5073031) On Cardiovascular Outcomes In Subjects With Inadequated Controlled Type 2 Diabetes And Established Cardiovascular Disease
F. Hoffmann - LA Roche Ltd
10
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
Cardiovascular Outcomes Study to Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With A Recent Acute Coronary yndrome (ACS) Event And Type 2 Diabetes Mellitus (T2D) (ALECARDIO Study)
F. Hoffmann-La Roche AG
11
PM Dr Biswa Mohan Biswal, Perubatan Nuklear
Kajian Klinikal
BreaST Cancer with Overexpression of ErbB2- Study of the Treatment Paradigm in Metastasis to BRAIN (BRAINSTORM).
Glaxo Smith Kline
12
PM Dr Zurkurnai Yusof, Perubatan
Kajian Klinikal
Effects Of Ivabradine In Patient With Stable Coronary Artery Disease Without Clinical Heart Failure. A Randomised Double Blind Placebo-Controlled International Multicenter Study
Institut de Researches Internationals Servier (I.R.I.S)
13
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
A Randomized, Doubl-Blind, Placebo-and Active- Controlled Study of Carisbamate in the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy Followed by a Blinded Extension Phase.
Johnson & Johnson Pharmaceutical
14
PM Dr. Zakuan Zainy Deris, Mikrobiologi
Kajian Klinikal
Comparison Activity of Carbepenem Testing E Ð Test Extended Study.
Johnson & Johnson Sdn Bhd
15
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled, Study Of The Effects Of Canagliflozin (JNJ-28431754) On Cardiovascular Outcomes In Adult Subjects With Type 2 Diabetes Mellitus (CANVAS Trial)
Johnson & Johnson Sdn. Bhd
16
Prof Dr Shaiful Bahari Ismail, Perubatan Keluarga
Kajian Klinikal
Hypoglycaemia in Sulphonylurea Treated Type 2 Diabetes Mellitus Subjects Undergoing Ramadhan Fasting.
Merck & Co Inc
17
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono-or Dual Combination Oral Antihyperglycemic Therapy.
Merck & Co Inc
18
Prof Dr Shaiful Bahari Ismail, Perubatan Keluarga
Kajian Klinikal
A Phase Iia, Multicenter, Randomised, Placebo and Active Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK3577 in Patients with Type 2 Diabetes Mellitus Who have Inadequate Glycemic Control
Merck Sharp & Dohme
19
PM Dr Zainal Darus, Perubatan
Kajian Klinikal
A Phase III, Multicenter, Double-Blind, Double-Dummy, Randomised, Flexible-dose, Comparative Study of MCI-196 versus Simvastatin for the Treatment of Dyslipidaemia in Subjects with Chronic Kidney Disease on Dialysis (incorporating a Placebo-controlled Withdrawal Phase)
Mitsubishi Tanabe Pharma Corporation
20
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
A Cross Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia & to Evaluate Perceptions and Practices of Physicians & Patients About Diabetes Management in Asia, Observational Study.
Novo Nordisk
21
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
The Effect of NovoMix¨ 30, Levemir or NovoRapid¨ (alone or in combination) in Subjects with Type 2 Diabetes Previously Treated with Other Anti-Diabetic Medication. A 24-Week,International, Prospective, Multi-Centre, Open-Labelled, Non-Interventional Study.
Novo Nordisk
22
Prof Dr Wan Mohamad Wan Bebakar, Perubatan
Kajian Klinikal
A 26 Week, Randomized, Open Labelled, Two Arm, Parallel Group, Treat-To -Target Trial Comparing Efficacy And Safety Of Double Insulin Analogue Combination (SIAC) Twice Daily (BID) With Biphasic Insulin Apart (BIASP) 30 BID, With Or Without Metformin,With Or Without DPP-4 Inhibitor, With Or Without Pioglitazone In Subjects With Type 2 Diabetes In Inadequate Glycemic Control On Once Or Twice Daily Premixed Or Self Mixed Insulin Regimen With oe Without OADs, trial Phase 3a
Novo Nordisk
23
Prof Dr Wan Mohamad Wan Bebakar, Perubatan
Kajian Klinikal
A 26 Week, Randomised, Controlled, Open-label, Multicentre, Multinational, Three-Arm, Treat-To-Target Trial Comparing Efficacy And Safety Of Three Different Dosing Regimens Of Either Soluble Insulin Basal Analogue (SIBA) Or Insulin Glargine With Or Without Combination With OAD Treatment, In Subjects With Type 2 Diabetes Mellitus, Trial Phase 3a
Novo Nordisk
24
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
An Open Label, Multi-Center, Long-Term Extension Study to Evaluate the Safety of Dutogliptin / PHX 1149T in Subjects with Type 2 Diabetes Mellitus.
Phenomix Corporation
25
Prof Dr Shaiful Bahari Ismail, Perubatan Keluarga
Kajian Klinikal
i-COMPARE (Investigation of Thiazide Diuretics Combination in Treatment of Moderate to Severe Primary Hypertension).
Sanofi Aventis
26
Prof Dr Wan Mohamad Wan Bebakar, Perubatan
Kajian Klinikal
A Randomized, Placebo-Controlled, 2 Arm Parallel-Group, Multicenter Study With A 24 Week Double Blind Treatment Period Assessing The Efficacy And Safety Of Lixisenatide In Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine And Metformin
Sanofi Aventis
27
PM Dr Zurkurnai Yusof, Perubatan
Kajian Klinikal
A multicenter, Randomized, Double Blind, Placebo-Controlled Study To Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin In Addition To Standard Of Care In Subjects With Type 2 Diabetes And Acute Coronary Syndrome.
Takeda Global Research & Development Center, Inc
 

International grants in 2008
 
NO NAME TYPE TITLE SPONSOR
1
Prof Dr Abdul Aziz Baba, Perubatan
Kajian Klinikal
A Randomized , Double-blind , Pilot Study Comparing the Safety and Efficacy of Betamarc Plus Chemotherapy to Chemotherapy Alone in the Prevention and Treatment of Cancer Anorexia and Anorexia and Cachexia Syndrome in Patients with Advanced Non-Small Cell Lung Cancer
Anaborex, Inc USA
2
Prof Dr. Amran Ahmed Shokri, Ortopedik
Kajian Klinikal
A Phase III Randomized, Double Blind, Parallel-Group Study of the Efficacy and Safety of Oral Dabigatran Etixilate (150 mg bid) compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic VenousThromboembolism Following Initial Treatment for At Least 5 days with a Parenteral Anticoagulant Approved for this Indication.
Boehringer Ingelheim
3
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
A randomized, double-blind, placebo controlled parallel group efficacy and safety study of BI1356 (5mg administered orally once daily) over 24 weeks, in drug na•ve or previously treated (6 weeks washout) type 2 diabetic patients with insufficient glycaemic control
Boehringer Ingelheim
4
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
A 78 Week, Open Label Extension To Trials Assessing the safety and Efficacy of BI 1356 (5mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients.
Boehringer Ingelheim
5
PM Dr Zurkurnai Yusof, Perubatan
Kajian Klinikal
A phase 3 randomized, Double-blind, Parallel-group, Multi-center Study of the safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely III Medical Subjects During and Following Hospitalization
Bristol - Mayers Squibb
6
Prof Dr Abdul Aziz Baba, Perubatan
Kajian Klinikal
An International, Multi-centre Open- Label 2-arm Phase III Trial of Adjuvant Bevacizumab in Triple Negative Breast Cancer
F Hoftman - La Roche Ltd
7
Prof Dr Ahmad Sukari Halim, Unit Sains Rekonstruktif
Geran Luar
Engineered Skin Substitute Using Chitosan Porous Skin Regenerating Template
INTERNATIONAL ATOMIC ENERGY AGENCY (IAEA)
8
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
A Randomized, Double-Blind, Placebo-Controlled, Double Dummy, Parallel Group, Multicenter, Dose Ranging Study in Subjects with Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally-Administered SGLT2 Inhibitor JNJ-28431754 with Sitagliptin as a Reference Arm
Janssen Cilag
9
PM Dr Mohd Jamil Yaacob, Psikiatri
Kajian Klinikal
A Multi-Center, Retrospective, Comparative Study to Investigate Drug Utilization Patterns And Treatment Period Associated With Atypical Antipsychotics Treatment in Schizophrenia and Schizoaffective Disorders: Aripiprazole,Olanzapine,Quetiapine and Risperidone.
Jenssen - Cilag
10
PM Dr Mohd Jamil Yaacob, Psikiatri
Kajian Klinikal
Pharmacoepidemiologic International Longitudinal Antipsychotic Registery.
Jenssen- Cilag
11
Dr. Che' Wan Aminud-din Hashim, Perubatan
Kajian Klinikal
A randomised, 4-week, placcebo-controlled, double-blind, 6 arm parallel group, dose-finding clinical trial, to assess the efficacy, safety and pharmacokinetics of three different doses of formoterol (6, 12 &18 µg, aclidinium bromide 200µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe Chronic Obstructive Pulmonary Disease.
Laboratories Almiral, S.A
12
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of  MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin
Merck & Co Inc
13
Prof Dr Shaiful Bahari Ismail, Perubatan Keluarga
Kajian Klinikal
A 76-week, Worldwide, Multicenter, Double-blind, Randomised, Placebo-controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When added to ongoing Therapy  With a Statin in patients with Hypercholesterolaemia or mixed Hyperlipidaemia.
Merck & Co USA
14
PM Dr Zurkurnai Yusof, Perubatan
Kajian Klinikal
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk and not Adequately Controlled with Atorvastatin 20 mg: A Comparison of Switching to a Combination Tablet Ezetimibe/Simvastatin (10mg/40mg) versus Doubling the Baseline Dose to Atorvastatin 40 mg
Merck & Co.
15
Prof Dr Wan Mohamad Wan Bebakar, Perubatan
Kajian Klinikal
A Worldwide, Multicenter, Double-Blind, Randomized, placebo-Controlled, Dose Ranging Study to Evaluate the efficacy, safety and Tolerability of MK-0736 When Added to Ongoing Therapy With Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) in Patients With Diabetes and Hypertension.
Merck & Co. Inc
16
PM Dr. Juwita Shaaban, Perubatan Keluarga
Kajian Klinikal
Observational study to evaluate safety and effectiveness of the free combination of and 80mg/160mg valsartanamlodipine 5mg/10mg in the treatment of hypertension.
Symbicort Maintenance and Reliever Therapy, Experience in Real Life Setting in Malaysia- ÔSmarterÕ Study.
Novartis
17
Prof Dato' Dr Mafauzy Mohamed, Perubatan
Kajian Klinikal
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of PHX1149T as Monotheraphy in Subjects With Type 2 Diabetes Mellitus
Phenomix Corporation San Diego, CA
18
Prof Dr Shaiful Bahari Ismail, Perubatan Keluarga
Kajian Klinikal
A randomized, double blind, placebo controlled study evaluating the glycaemic effect of rimonabant added to metformin in patients with type 2 diabetes insufficiently controlled with metformin monotherapy-TOCCATA
Sanofi Adventis
19
Prof Dr Abdul Aziz Baba, Perubatan
Kajian Klinikal
A Multicenter, Double Blind, Placebo Controlled, Randomized Study of TroVax ¨ vs. Placebo in the First Line Treatment of Patients with Metastatic Colorectal Cancer Receiving Standard of Care.
Sanofi Aventis
20
Prof Dr Wan Mohamad Wan Bebakar, Perubatan
Kajian Klinikal
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, 24-Week Study Followed by an  Extension Assessing The Efficacy and Safety of AVE0010 in two Titration Regimens on top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled with Metformin
Sanofi Aventis
21
Prof Dr. Mohd Suhaimi Ab. Wahab, Farmakologi
Kajian Klinikal
A Retrospective Study to Assess the Clinical Burden of Community-Acquired Pneumonia (CAP) and Invasive Pneumococcal Disease (IPD)
Wyeth Research Division Of Wyeth Pharmaceuticals inc. Philedelphia
 

We have 1194 guests and no members online